Abstract: The present invention relates to an oral solid dosage form comprising N2-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alaninamide, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof as an active ingredient, which has good dissolution and storage-stability. When the oral solid dosage form is a tablet, the tablet can be prepared while inhibiting tableting troubles from low content to high content of the active ingredient.

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: Provided are modified release compositions in a solid oral dosage form comprising racemic amisulpride, or pharmaceutically acceptable salts thereof, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: A power system includes: a rotating body; a housing that accommodates the rotating body; and a storage portion that is provided in a bottom of the housing to store a liquid medium. The rotating body is partially located in the storage portion, and an inner surface of the housing includes a protrusion that extends above the rotating body to intersect with a rotation direction of the rotating body.

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

Abstract: A detection apparatus includes a second detection unit configured to detect lowering of a light reflectance of a reflection portion based on an output value based on light received by a light receiving portion while an object is moving on a conveyance path, without depending on at least a part of output values output based on light received by the receiving unit while the object is stopped on the conveyance path.

Abstract: A detection apparatus includes a second detection unit configured to detect lowering of a light reflectance of a reflection portion based on an output value based on light received by a light receiving portion while an object is moving on a conveyance path, without depending on at least a part of output values output based on light received by the receiving unit while the object is stopped on the conveyance path.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: A power system includes: an electric motor that drives wheels of a vehicle; a transmission that is disposed on power transmission paths between the electric motor and the wheels; and a differential gear system that distributes output power shifted by the transmission to the wheels. The transmission includes: a first gear mechanically connected to the electric motor; a second gear that has a rotation axis in common with the first gear and is mechanically connected to a differential gear casing of the differential gear system; a pinion gear that meshes with the first gear and the second gear; and a pinion holder that rotatably supports the pillion gear. The pinion holder has a pinion gear supporting portion which is disposed on a side of the differential gear casing to support the pinion gear, relative to a meshing portion between the second gear and the pinion gear.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: A power system includes: a rotating body; a housing that accommodates the rotating body; and a storage portion that is provided in a bottom of the housing to store a liquid medium. The rotating body is partially located in the storage portion, and an inner surface of the housing includes a protrusion that extends above the rotating body to intersect with a rotation direction of the rotating body.

Abstract: A power system includes: an electric motor that drives wheels of a vehicle; a transmission that is disposed on power transmission paths between the electric motor and the wheels; and a differential gear system that distributes output power shifted by the transmission to the wheels. The transmission includes: a first gear mechanically connected to the electric motor; a second gear that has a rotation axis in common with the first gear and is mechanically connected to a differential gear casing of the differential gear system; a pinion gear that meshes with the first gear and the second gear; and a pinion holder that rotatably supports the pillion gear. The pinion holder has a pinion gear supporting portion which is disposed on a side of the differential gear casing to support the pinion gear, relative to a meshing portion between the second gear and the pinion gear.